[Daratumumab for multiple myeloma]

Carolyne Croizier; Sébastien Bailly

doi:10.1016/j.bulcan.2018.09.003

[Daratumumab for multiple myeloma]

Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.

[Article in French]

Authors

Carolyne Croizier¹, Sébastien Bailly²

Affiliations

¹ CHU de Clermont-Ferrand, service thérapie cellulaire et hématologie clinique, 1, rue Lucie-Aubrac, 63100 Clermont-Ferrand, France. Electronic address: ccroizier@chu-clermontferrand.fr.
² CHU de Clermont-Ferrand, service thérapie cellulaire et hématologie clinique, 1, rue Lucie-Aubrac, 63100 Clermont-Ferrand, France.

PMID: 30430991
DOI: 10.1016/j.bulcan.2018.09.003

Abstract

Daratumumab is a monoclonal antibody that targets CD38. It has an anti-tumor action on the myeloma cell and an immunomodulatory action. For relapsing and/or refractory myeloma patients, daratumumab is effective both alone and in combination and significantly improves progression-free survival. Daratumumab has been approved in 2016 in France for treatment of relapses or refractory multiple myeloma.

Keywords: Anticorps monoclonal; Daratumumab; En rechute ou réfractaire; Monoclonal antibody; Multiple myeloma; Myélome multiple; Relapsed or refractory.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / administration & dosage
Dexamethasone / administration & dosage
Disease-Free Survival
Drug Resistance, Neoplasm
Humans
Lenalidomide
Multiple Myeloma / drug therapy*
Neoplasm Recurrence, Local / drug therapy
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab
Thalidomide
Bortezomib
Dexamethasone
Lenalidomide